Interesting that in vitro, T-705 seems less effective than the "SOC," but in vivo more so (one wonders how it got developed to the point of being tried in vivo, given that most drugs that look iffy in cell cultures are dropped right there). I haven't studied the preclinical work in this area very closely, is this a common occurrence? Murine data makes it look like a serious, but early competitor. Still, just taking it into humans is worth 11% when it's behind in development compared to peramivir and others? Sheesh, I'm beginning to figure your conspiracy theories about the trading in BCRX are correct. In my experience, these short attacks in stocks that you like usually blow over after a couple of months.
But, as Kenhott points out, news drivers are lacking for a while, and the distinct possibility of a financing looms. Dumb shorts? Nah, just the usual short-the-company-that needs-money-and-science-be-damned crowd. Given the advantages they have over us peons (i.e. Cox kneeling in front of them wearing bib, elbowing Lief aside), it usually works. The theory? BCRX got their bird flu contract, so what's left for a while? Whatever, I bought a bit more, but will not add any more until the financing shows up.
Seems to me, in good companies, you want to buy any weakness that attends a financing on half decent terms these days. This would be another such case, as that's when the slimeballs find it convenient to cover.
Cheers (and apologies for rabble-rousing incoherence, but I ain't editing), Tuck |
